EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSPLAG00000000398
Gene Symbol: MAP3K12
4 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12-Like

Ensembl ID : ENSPLAG00000003124
Gene Symbol: LOC106964810
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSPLAG00000021630
Gene Symbol: MAP3K13
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSPLAG00000003973
Gene Symbol: MAP3K5
3 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSPLAG00000008395
Gene Symbol: MAP3K9
3 Cross references
193 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSPLAG00000022349
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSPLAG00000011152
Gene Symbol: MLNR
3 Cross references
174 Possible Orthologues:

Muscarinic Acetylcholine Receptor M4-Like

Ensembl ID : ENSPLAG00000005894
Gene Symbol: LOC106956603
2 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSPLAG00000006337
Gene Symbol: NPR1
3 Cross references
190 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSPLAG00000015111
Gene Symbol: NPR3
3 Cross references
207 Possible Orthologues:

Neprilysin-Like

Ensembl ID : ENSPLAG00000010783
Gene Symbol: LOC106959747
2 Cross references
199 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSPLAG00000012452
Gene Symbol: LOC106954293
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).